ResearcherNational Yang Ming Chiao Tung UniversityActive in the last 2 years

Bor‐Uei Shyr

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2412-2745; OpenAlex author ID A5009752385, A5073519096. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor suppressor gene ZNF382. Co-author DOI 10.1016/j.phymed.2024.155860 ↗
Propensity score-matched comparison of the oncological feasibility and survival outcomes for pancreatic adenocarcinoma with robotic and open pancreatoduodenect… Co-author DOI 10.1007/s00464-021-08437-7 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shin‐E Wang · 2 shared papers, 2022–2024 · strength 0.41
- Paper Propensity score-matched comparison of the oncological feasibility and survival outcomes for pancreatic adenocarcinoma … DOI 10.1007/s00464-021-08437-7 ↗
- Paper Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor sup… DOI 10.1016/j.phymed.2024.155860 ↗
Yi‐Ming Shyr · 1 shared paper, 2022 · strength 0.22
- Paper Propensity score-matched comparison of the oncological feasibility and survival outcomes for pancreatic adenocarcinoma … DOI 10.1007/s00464-021-08437-7 ↗
Kai-Ru Zhuang · 1 shared paper, 2024 · strength 0.19
- Paper Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor sup… DOI 10.1016/j.phymed.2024.155860 ↗
Shu‐Ling Fu · 1 shared paper, 2024 · strength 0.19
- Paper Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor sup… DOI 10.1016/j.phymed.2024.155860 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.